Search Results - TherapeuticArea+%3e+Oncology

555 Results

Sort By:

Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy

Summary: Scientists at the National Cancer Institute (NCI) have developed a novel tightly regulated drug-responsive, membrane-bound IL-12 cytokine platform, that enhances anti-tumor efficacy in adoptive cell therapy (ACT) with engineered T-cells (CAR, TCR, TILs) while improving safety. The NCI seeks research co-development partners and/or licensees...

Published: 5/14/2026 | Updated: 5/14/2026 | Inventor(s): Steven Rosenberg, Sanghyun (Peter) Kim

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Oncology, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

Angubindin-1 Peptide for Transient Blood-Brain Barrier Opening to Boost Chemotherapy in Malignant Glioma

This technology includes a first-in-class synthetic peptide, angubindin-1, designed to temporarily relax the blood-brain barrier (BBB)—the tightly sealed network of brain blood vessel cells that normally blocks most drugs—from the inside. By binding the tricellular tight-junction protein angulin-1/LSR, the peptide creates a reversible “molecular...

Published: 4/30/2026 | Updated: 4/30/2026 | Inventor(s): Sadhana Jackson

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Neurology, TherapeuticArea > Oncology, Collaboration Sought > Licensing

DNA Methylation-Based Cancer Diagnostics for Accurate Tumor Classification

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a collection of T-cell receptors (TCRs) that specifically target the mutated KRAS antigen. This technology encompasses a DNA methylation–based diagnostic platform designed to improve the accuracy and consistency of cancer classification,...

Published: 4/23/2026 | Updated: 4/10/2026 | Inventor(s): Kenneth Aldape, Ziedulla Abdullaev, Rustamzhon Turakulov, Stefania Pittaluga, Mark Raffeld, Elaine Jaffe, Omkar Singh, Antonios Papanicolau-Sengos

Keywords(s):

Category(s): Application > Diagnostics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia

Summary: The NCI seeks research co-development partners or licensees for Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia. Description of Technology: Acute myeloid leukemia (AML) is a rare form of blood cancer affecting myeloid stem and progenitor cells, associated with a poor prognosis...

Published: 4/10/2026 | Updated: 4/10/2026 | Inventor(s): Vid Leko, Aidan Pursley, Kenichi Hanada, Zhiya Yu, Catherine Ade, James Yang

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Humanized 40H3 Antibody

Summary: The NCI seeks research co-development partners or licensees for monoclonal antibodies that specifically target cancer-expressed EGFR. Description of Technology: Epidermal growth factor receptor (EGFR) is a well-known oncogenic driver in lung cancer, head and neck cancer, glioblastoma multiforme (GBM) and other cancers. NCI inventors have...

Published: 2/5/2026 | Updated: 2/5/2026 | Inventor(s): David Fitzgerald, Antonella Antignani, Robert Sarnovsky

Keywords(s):

Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions

Summary: Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in-class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used...

Published: 5/12/2026 | Updated: 9/29/2025 | Inventor(s): Zheng-gang Liu, Swati Choksi, PeiXing Wan, Yeon-Ji Park

Keywords(s):

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology, Application > Diagnostics, Application > Therapeutics

Combination PDL1 and TGF Beta Blockade in Patients with HPV-Associated Malignancies

Summary: The National Cancer Institute (NCI) seeks collaborations and licensees for a method to block PD-L1 and TGF-beta for the treatment of HPV-associated malignancies. Description of Technology: Advanced or relapsed human papillomavirus (HPV)-associated cancers are incurable and many of these diseases do not have a standard second line therapy....

Published: 11/26/2025 | Updated: 9/29/2025 | Inventor(s): Julius Strauss, James Gulley, Christian Hinrichs

Keywords(s):

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Oncology

Identification and Characterization of HLA-A24 Agonist Epitopes of MUC1 Oncoprotein

Summary: The National Cancer Institute (NCI) seeks co-development partners and licensees for a human cytotoxic T lymphocyte agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), in a cancer vaccine or T-cell targeted therapy to target many tumor types. Description of Technology: Many...

Published: 9/29/2025 | Updated: 9/29/2025 | Inventor(s): Jeffrey Schlom, Kwong-Yok Tsang

Keywords(s):

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Oncology

Novel Human Immunogenic Epitopes of the Human Endogenous Retrovirus ERVMER34-1

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for the clinical translation of novel peptide-based therapeutic cancer vaccines derived from ERVMER34-1, a human endogenous retrovirus (HERV) antigen, offering a unique opportunity to address a significant unmet need in the treatment of various carcinomas. Description...

Published: 9/29/2025 | Updated: 9/29/2025 | Inventor(s): Jeffrey Schlom, Duane Hamilton, Claudia Palena, Renee Donahue

Keywords(s):

Category(s): TherapeuticArea > Immunology, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Vaccines

Innovative Antibody Conjugation Technology for Therapeutic and Diagnostic Applications

This pioneering technology introduces a novel method for conjugating antibodies, designed to dramatically enhance their therapeutic and diagnostic performance. By improving both binding efficiency and target specificity, this approach overcomes critical limitations of existing antibody-based therapies and imaging tools. The result is a versatile platform...

Published: 4/14/2026 | Updated: 9/22/2025 | Inventor(s): Parinaz Fathi, Frank Borris, Kaitlyn Sadtler

Keywords(s):

Category(s): Application, Application > Therapeutics, Application > Diagnostics, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease

1 2 3 4 5 6 7 8 9 10 ...